Medtronic (MDT)
Health Care · Medical devices and diagnostics · NYSE
Global medical device leader deploying pacemakers, defibrillators, spinal implants, surgical robotics, and diabetes management systems to alleviate pain, restore health, and extend life across 150+ countries.
What Medtronic does
Medtronic plc is a global healthcare technology company headquartered in Ireland that develops, manufactures, and distributes device-based medical therapies and services. The company operates three primary reportable segments: Cardiovascular Portfolio (cardiac rhythm management, structural heart, coronary and vascular products), Neuroscience Portfolio (neurological and spinal therapies), and Medical Surgical Portfolio (surgical instruments, respiratory solutions, and other medical devices). Medtronic serves healthcare systems, physicians, clinicians, and patients in over 150 countries, with a recent spin-off of its Diabetes Business (MiniMed Group IPO in March 2026) now conducted separately.
Themes: Cardiac devices and heart failure management, Implantable medical devices, Minimally invasive cardiology, Remote patient monitoring, Neuroscience and spinal care, Digital health and data analytics, MRI-compatible implantable devices, Leadless pacing technology
Fundamentals
- Price$93.35 as of 2026-08-21 close
- Market cap$119.5B as of 2026-08-21
- 1-year return+2.5% 2025-08-21 close $91.10 → 2026-08-21 close $93.35
- P/E24.25 as of 2026-08-24
- Net margin+13.2% as of 2026-08-24
- Gross margin+65.8% as of 2026-08-24
- ROE+9.8% as of 2026-08-24
- Debt / equity0.57 as of 2026-08-24
- Revenue growth (YoY)+8.4% as of 2026-08-24
- Revenue CAGR (3y)+5.2% SEC XBRL
- Beta0.57 as of 2026-08-24
- Last reported earnings2026-06-03 SEC EDGAR Form 8-K (Item 2.02)
Dividend: yield +3.5%; at least 5 years of non-decreasing per-share dividends (SEC XBRL) — we do not hold the year before it, so the real streak may be longer.
How MDT compares in its sector
- price-to-earnings ratiomiddle range 203 covered Health Care peers, as of 2026-08-24
- net profit margintop 25% 504 covered Health Care peers, as of 2026-08-24
- operating margintop 25% 504 covered Health Care peers, as of 2026-08-24
- gross marginmiddle range 384 covered Health Care peers, as of 2026-08-24
- return on equitytop 25% 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- indicated dividend yieldtop 25% 71 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)top 10% 493 covered Health Care peers, as of FY2026
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
MDT is not currently in any published Top 10 list. Its scores are below.
Long-term score
53.2 #384 of 987 scored · #22 of 57 in Health Care
Capital return 71st (consecutive years of dividend increases 5 years) and financial health 60th (free cash flow margin 14.9%, debt to equity 0.6); weakest is profitability (44th, return on equity 9.9%, operating margin 17.8%).
Short-term score
64.3 #70 of 1,704 scored · #22 of 240 in Health Care
Volume and participation 80th: it gapped 4.6% above the previous close and has not traded back through the level it left behind — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed; trend 70th: the price is 12% above the average price paid over the period covered, so the typical buyer over that stretch is showing a gain; weakest is setup 47th: day-to-day price swings are wider than usual versus its own recent 6-month history (wider than about 71% of it).
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
Dividend coverage (FY2026)
Covered by reported results. In FY2026, MDT's dividend was covered by reported results (earnings payout 76%, free-cash-flow payout 67%). This describes past coverage, not a forecast.
- Earnings payout76% dividends / net income
- Free-cash-flow payout67% dividends / (operating cash flow − capex)
Coverage derived from reported SEC EDGAR XBRL figures for FY2026 (dividends paid vs. net income and free cash flow, same fiscal year). This describes PAST coverage for one fiscal year — it does not predict whether a dividend will be maintained, raised, or cut, and a one-year payout ratio can be distorted by non-recurring items. Informational only — not financial advice.
How Medtronic looks technically
Medtronic (MDT) is trading 3.8% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed below its 200-day average about 93 trading days ago — a "death cross", a bearish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 29, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 68, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 3 trading days ago.
Trend
9
| Distance from the 200-day | it is trading 3.8% above its 200-day average, the long-term trend line — a longer-term uptrend | +3.8% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $84.36 | $84.36 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $89.95 | $89.95 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing high 24 calendar days ago — the swings before that are what the structure reading is measured on | 24 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in the fourth leg, a pullback against that upward direction; the labelling fails if price closes below 85.99. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible upward five-wave sequence, in wave 4 (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 93 trading days ago — a "death cross", a bearish long-term signal | 93 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 3.8% above | +3.8% |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 29, with buyers in control | 28.5 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 68, neither overbought (above 70) nor oversold (below 30) | 68.4 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($84.95 to $94.72) — its "stochastic" reading is 86 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 86.0 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 20 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $106.33 | $106.33 |
|---|---|---|
| From the 52-week high | it is 12.2% below its 52-week high (its highest price of the past year) | -12.2% |
| Above the 52-week low | it is 27.3% above its 52-week low (its lowest price of the past year) | +27.3% |
| Below the 52-week high | it is 12.2% below its highest point of the past year | 12.2% |
| Since a 20-day breakout | it made a new 20-day high about 3 trading days ago | 3 sessions |
| Since a 55-day breakout | it made a new 55-day high about 3 trading days ago | 3 sessions |
| All-time high | its highest closing price on record is $135.89 (set on 2021-09-09) | $135.89 |
| Given back of the 52-week move | over the past year its closes ranged ($73.75 to $105.35), and it has recovered close to two thirds of its fall from last year’s high — 62% of it. Chart-watchers call 61.8%-65% given back the "golden pocket", and this is inside it — for this company that is $93.28 to $94.29. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 62.0% |
| From the all-time high | it is 31.3% below its all-time high | -31.3% |
| Nearest price level | it is sitting right on a resistance level at $93.68 — a price it turned at six times since 2025-01-28, most recently on 2025-10-15. Since 2024-08-21 it has 7 such levels below the current price and 3 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +0.3% |
| All-time low | its lowest closing price on record is $11.75 (set on 1996-07-31) | $11.75 |
| Above the all-time low | it is 694.5% above its all-time low | +694.5% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are wider than usual versus its own recent 6-month history (wider than about 71% of it) | 71st percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $2.14 between its high and its low — about 2.3% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $2.14 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $83.01 and $94.67 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $83.01 – $88.84 – $94.67 |
| Typical daily range (% of price) | its price moves about 2.3% in a typical session — calmer than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 2.3% |
| Stretch from the 200-day average | it is trading 1.6 daily ranges above its 200-day average price (3.8% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 1.6 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.11× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a doji | 3 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 3 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.3% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.3% |
|---|---|---|
| Open gap | it gapped 4.6% above the previous close 52 sessions ago and has not traded back through the level it left behind at 73.75 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +4.6% |
| Gap filled | a 2.4% gap up opened on 2026-07-28 has been "filled" 15 sessions ago — price traded back through the level the gap left behind, and it took 3 sessions to close | 15 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 11.0 percentage points (the stock gained 13.4% while the market gained 2.3%) | +11.0% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 16.4 percentage points (the stock gained 19.4% while the market gained 3.1%) | +16.4% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 14.7 percentage points (the stock lost 3.6% while the market gained 11.1%) | -14.7% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 18.0 percentage points (the stock gained 2.5% while the market gained 20.5%) | -18.0% |
Signal agreement
2
| Bullish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
|---|---|---|
| Bearish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, lagging the market over 6 months, near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 3 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 14% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 2.7% of the share price. | +13.6% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 7% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $87.01 — a volume-weighted average of daily closes over 157 sessions, not a true tick-by-tick VWAP. | +7.3% |
|---|---|---|
| Vs the average paid since it last reported | the price is 12% above the average price paid since it last reported on 2026-06-03 (its 8-K), so the typical buyer over that stretch is showing a gain. That average is $83.64 — a volume-weighted average of daily closes over 53 sessions, not a true tick-by-tick VWAP. | +11.6% |
Price levels it has turned at before
MDT last closed at $93.35 on 2026-08-21. Since 2024-08-21 it has turned at 7 prices below its last close and 3 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $93.68 | Resistance | 0.3% above the last close | turned there six times · 2025-01-28 to 2025-10-15 |
| $91.51 | Support | 2.0% below the last close | turned there 8 times · 2024-09-04 to 2025-10-01 |
| $95.72 | Resistance | 2.5% above the last close | turned there five times · 2025-03-10 to 2026-02-17 |
| $88.22 | Support | 5.5% below the last close | turned there 14 times · 2024-08-30 to 2026-07-28 |
| $85.21 | Support | 8.7% below the last close | turned there 7 times · 2025-02-18 to 2026-07-16 |
| $105.92 | Resistance | 13.5% above the last close | turned there twice · 2025-11-26 to 2026-02-04 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 4 of five, a pullback against that direction.
This labelling fails — stops being a possible reading at all — if it closes below $85.99.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
On past moves of this shape the leg has usually ended somewhere between $85.99 and $86.62 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Tested and reclaimed 200-day support · Broke out to a new 20-day high · in a strong, established uptrend (ADX) · lagging the market · At the top of its 14-day range (stochastic above 80) | Learn: moving average · golden cross · adx · rsi · breakout
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.79 mean, 1=Strong Buy…5=Strong Sell) — 25 analysts
- Mean price target$98.44 range $78.00 – $121.00; median $100.00
Analyst estimates, as of 2026-08-22. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for MDT
- Consensus EPS estimate$1.39 next reporting period, as of 2026-08-22
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Separation of Diabetes Business: In March 2026, Medtronic spun off MiniMed as an independent public company, creating operational, financial, and strategic risks from the loss of this business segment and ongoing integration challenges.","Regulatory and compliance complexity: Operating in 150+ countries subjects Medtronic to varying medical device regulations and potential regulatory changes that could impact product approvals, manufacturing standards, and market access.","Product liability and litigation: The filing discloses significant litigation charges and product liability exposure inherent to medical device manufacturing, which could result in material financial and reputational impacts."]
What changed in the latest 10-Q
AI-assisted comparison of MDT's 10-Q filed 2026-02-24 against the prior one filed 2025-11-25.
Management's Discussion & Analysis (MD&A)
- Added:
- In newer filing (2026-02-24): Reference to 'three and nine months ended January 23, 2026' instead of 'three and six months ended October 24, 2025'
- In newer filing (2026-02-24): Addition of 'Certain litigation charges, net' line item in three months ended January 23, 2026 reconciliation ($62 million income before taxes)
- In newer filing (2026-02-24): Three months ended January 23, 2026 includes $30 million accelerated amortization footnote (1) compared to $46 million in prior period
- In newer filing (2026-02-24): Three months ended January 23, 2026 footnote (3) explicitly references 'costs associated with the Company's June 2021 decision to stop the distribution and sale of the Medtronic HVAD System'
- In newer filing (2026-02-24): Three months ended January 24, 2025 comparative period includes 'Medical device regulations' adjustment line item
- In newer filing (2026-02-24): Nine months ended January 23, 2026 reconciliation includes 'Other' adjustment line item ($39 million)
- Removed:
- In older filing (2025-11-25): 'Computed based on the amounts in thousands' language removed and replaced with 'computed based on the actual amounts'
- In older filing (2025-11-25): Three months ended October 24, 2025 does not separately present 'Certain litigation charges, net' line
- In older filing (2025-11-25): Three months ended October 25, 2024 includes specific 'Certain tax adjustments, net' description footnote (5) that is not replicated in newer filing's comparative period presentation
- Reworded:
- Older filing states amounts 'computed based on the amounts in thousands,' newer filing states 'computed based on the actual amounts'
- Older filing footnote (2) for October 24, 2025 period states charges relate to 'employee termination benefits and facility related and contract termination costs'; newer filing expands to include 'and asset write offs'
- Older filing footnote (3) for October 24, 2025 combines Diabetes separation and HVAD System costs in single explanation; newer filing separates Diabetes charges from HVAD System costs in footnote (3)
- Notes:
- Newer filing appears truncated at end of nine months ended January 24, 2025 reconciliation table, preventing full comparison of that period's details
- Page numbers differ (36-38 in newer vs. 32-34 in older), reflecting different document lengths
- The periods covered differ materially: newer filing covers Q3 ended January 23, 2026 (9 months ended same date), older filing covers Q1 ended October 24, 2025 (6 months ended same date), making some changes attributable to different reporting periods rather than policy changes
Risk Factors
- Added:
- In newer filing (2026-02-24), Item 2 share repurchase table covers third quarter of fiscal year 2026 with periods 10/25/2025-11/21/2025, 11/22/2025-12/26/2025, and 12/27/2025-1/23/2026, showing 917,675 total shares purchased at $92.63 average price
- In newer filing (2026-02-24), Item 5 includes Rule 10b5-1 Director and Officer Trading Arrangements disclosure stating none of directors or officers adopted or terminated such arrangements during quarter ended January 23, 2026
- Removed:
- Older filing (2025-11-25) Item 2 share repurchase table for second quarter of fiscal year 2026 with periods 7/26/2025-8/22/2025, 8/23/2025-9/26/2025, and 9/27/2025-10/24/2025, showing 3,300,161 total shares purchased at $93.54 average price is not present in newer filing
- Older filing (2025-11-25) Item 5 Exchange Act Section 3(r) Disclosure regarding Medtronic's engagement with Russia's Federal Security Service is not present in newer filing
- Reworded:
- Currency exchange rate derivative instruments outstanding date changed from October 24, 2025 ($20.6 billion) in older filing to January 23, 2026 ($19.9 billion) in newer filing
- Net unrealized gain position on currency contracts changed from $100 million at October 24, 2025 (older) to $142 million at January 23, 2026 (newer)
- Interest rate sensitivity change from $86 million (October 24, 2025) in older filing to $89 million (January 23, 2026) in newer filing for 50 basis point change impact
- Reference to Note 8 changed from 'Note 8 to' in older filing to 'Note 8 in' in newer filing regarding consolidated financial statements
- Reference to Note 16 changed from 'Note 16 to' in older filing to 'Note 16 in' in newer filing regarding consolidated financial statements
- Notes:
- Page numbers differ between filings (57-60 in newer vs 52-53 in older), reflecting different document lengths
- The removals represent standard quarterly updates reflecting different reporting periods, not substantive deletions of policy or disclosure frameworks
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 3 open-market sales by insiders in the last 90 days.
- Last 90 days0 buys · 3 sells ($594897) — 2 selling insiders
- Last 180 days0 buys · 3 sells ($594897) — 2 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-07-08. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about MDT's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Congressional trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 15 matched disclosures for MDT from U.S. House Clerk Periodic Transaction Report filings.
Congressional trading disclosures →Short interest (FINRA)
MDT had 18,120,230 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
MDT had 1.42% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 2.37 days to cover at the same settlement.
- Reported short interest (shares) 18,120,230
- Short interest (% of shares outstanding) 1.42%
- Prior settlement (shares) 19,025,990
- Reported change -4.76%
- Days to cover (reported) 2.37
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Abbott Laboratories (ABT)
- Boston Scientific (BSX)
- Philips Healthcare
- GE HealthCare
- Siemens Healthineers
- Johnson & Johnson (JNJ)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare MDT vs…
Medtronic is found in…
Frequently asked questions
What does Medtronic (MDT) do?
Medtronic plc is a global healthcare technology company headquartered in Ireland that develops, manufactures, and distributes device-based medical therapies and services. The company operates three primary reportable segments: Cardiovascular Portfolio (cardiac rhythm management, structural heart, coronary and vascular products), Neuroscience Portfolio (neurological and spinal therapies), and Medical Surgical Portfolio (surgical instruments, respiratory solutions, and other medical devices).
What sector is Medtronic (MDT) in?
Medtronic (MDT) is classified in the Health Care sector. Its industry is Medical devices and diagnostics. It trades on NYSE.
Does MDT pay a dividend?
Yes — Medtronic (MDT) pays a dividend, with an indicated yield of about 3.50% and at least 5 years of non-decreasing per-share dividends (SEC EDGAR XBRL) — we do not hold the year before it, so the real streak may be longer (market data, as of 2026-08-24). Informational only — not financial advice.
Who are Medtronic's (MDT) competitors?
Notable peers of Medtronic (MDT) include Abbott Laboratories, Boston Scientific, Philips Healthcare, GE HealthCare and Siemens Healthineers. This peer set is informational only — not financial advice.
Has there been recent Congressional stock trading in MDT?
Yes — we hold 15 matched STOCK Act disclosures for MDT from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is Medtronic (MDT) overbought or oversold right now?
Medtronic (MDT) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 68, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on MDT come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.